trending Market Intelligence /marketintelligence/en/news-insights/trending/jOqNiktOxdOVVpApEOj_eA2 content esgSubNav
In This List

Mylan launches generic version of seizure injections

Blog

Insight Weekly: M&A outlook; US community bank margins; green hydrogen players' EU expansion

Blog

Global M&A by the Numbers: Q2 2022

Blog

Insight Weekly: US bank M&A; low refinancing eases rates impact; Texas crypto mining booms

Blog

Infographic 2022 Top Tech Trends Shaping Corporations


Mylan launches generic version of seizure injections

Mylan NV launched a generic version of Pfizer Inc.'s Cerebyx injection in the U.S.

The fosphenytoin sodium injections will be available in single-use vials for the treatment of certain types of seizures.

The treatment had U.S. sales of approximately $36.3 million for the 12 months ending Oct. 31, according to IMS Health.